These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 912647)

  • 1. Tumor growth patterns in multiple myeloma.
    Hokanson JA; Brown BW; Thompson JR; Drewinko B; Alexanian R
    Cancer; 1977 Mar; 39(3):1077-84. PubMed ID: 912647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission maintenance therapy for multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):147-52. PubMed ID: 1111463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unmaintained remissions in multiple myeloma.
    Alexanian R; Gehan E; Haut A; Saiki J; Weick J
    Blood; 1978 Jun; 51(6):1005-11. PubMed ID: 647110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expansion of the growth fraction in multiple myeloma with alkylating agents.
    Salmon SE
    Blood; 1975 Jan; 45(1):119-29. PubMed ID: 803104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The growth fraction of human myeloma cells.
    Drewinko B; Alexanian R; Boyer H; Barlogie B; Rubinow SI
    Blood; 1981 Feb; 57(2):333-8. PubMed ID: 7448427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors in multiple myeloma.
    Alexanian R; Balcerzak S; Bonnet JD; Gehan EA; Haut A; Hewlett JS; Monto RW
    Cancer; 1975 Oct; 36(4):1192-201. PubMed ID: 1175123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
    Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients.
    Belch A; Shelley W; Bergsagel D; Wilson K; Klimo P; White D; Willan A
    Br J Cancer; 1988 Jan; 57(1):94-9. PubMed ID: 3279997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of tumor growth and regression in IgG multiple myeloma.
    Sullivan PW; Salmon SE
    J Clin Invest; 1972 Jul; 51(7):1697-708. PubMed ID: 5040867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy for multiple myeloma.
    Alexanian R; Salmon S; Bonnet J; Gehan E; Haut A; Weick J
    Cancer; 1977 Dec; 40(6):2765-71. PubMed ID: 589554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone healing in multiple myeloma with melphalan chemotherapy.
    Rodriguez LH; Finkelstein JB; Shullenberger CC; Alexanian R
    Ann Intern Med; 1972 Apr; 76(4):551-6. PubMed ID: 4640313
    [No Abstract]   [Full Text] [Related]  

  • 12. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
    San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Deraedt W; Cakana A; van de Velde H; Richardson PG
    J Clin Oncol; 2013 Feb; 31(4):448-55. PubMed ID: 23233713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute leukemia in multiple myeloma.
    Gonzalez F; Trujillo JM; Alexanian R
    Ann Intern Med; 1977 Apr; 86(4):440-3. PubMed ID: 403840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study.
    Alberts DS; Salmon SE
    Cancer Chemother Rep; 1975; 59(2 Pt 1):345-50. PubMed ID: 1097093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early plasma cell recruitment in multiple myeloma following chemotherapy.
    Ucci G; Riccardi A; Dörmer P; Danova M; Luoni R
    Cell Tissue Kinet; 1988 Nov; 21(6):405-9. PubMed ID: 3251633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide.
    Bergsagel DE; Cowan DH; Hasselback R
    Can Med Assoc J; 1972 Nov; 107(9):851-5. PubMed ID: 4653931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy versus melphalan and prednisone in multiple myeloma.
    Gruber A; Osby E
    Chemioterapia; 1987 Jun; 6(2 Suppl):725-6. PubMed ID: 3509531
    [No Abstract]   [Full Text] [Related]  

  • 19. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
    Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
    Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of multiple myeloma.
    San Miguel JF; Bladé Creixenti J; García-Sanz R
    Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.